Abstract
Background Oral microbial therapy has been studied as an intervention for a range of gastrointestinal and immunological disorders. Though emerging research suggests microbial exposure may intimately affect the gastrointestinal system, motility, and host immunity in a pediatric population, data has been inconsistent and variable, with the majority of prior studies conducted in neither a randomized nor placebo-controlled setting. The aim of this placebo-controlled study was to evaluate efficacy of a synbiotic (a prebiotic and rationally-defined microbial consortia) on increasing weekly bowel movement frequency in constipated children.
Methods Sixty-four children (3-17 years of age) were randomized to receive a synbiotic composition (n=33) comprised of mixed-chain length, prebiotic oligosaccharides and nine microbial strains or placebo (n=31) for 84 days. Stool microbiota was analyzed using shotgun metagenomic sequencing on samples collected at baseline (T1) and completion (T2). The primary outcome was change from baseline of Weekly Bowel Movements (WBMs) in children compared to placebo.
Results Treatment with a multi-strain synbiotic significantly (p < 0.05) increased the number of WBMs in children with low bowel movement frequency (< 4 WBMs and < 5 WBMs), irrespective of broadly distinctive microbiome signatures at baseline. Metagenomic shotgun sequencing revealed that low baseline microbial richness in the treatment group significantly anticipated improvements in constipation (p = 0.00074).
Conclusions These findings suggest the potential for (i) multi-species synbiotic interventions to improve digestive health in a pediatric population and (ii) bioinformatics-based methods to predict response to microbial interventions in children.
Impact Synbiotic microbial treatment exerted functional improvements in the number of spontaneous Weekly Bowel Movements in children compared to placebo
Intervention induced a significant bifidogenic effect in children compared to placebo
All administered probiotic species were enriched in the gut microbiome of the intervention group compared to placebo
Baseline microbial richness demonstrated potential as a predictive biomarker for response to intervention
Competing Interest Statement
BTT and GS led data analysis and were not involved in study design or trial execution. JV, AF, EAM, CEM, and JFP are members of the Seed Health Scientific board. BTT, GS, NV, PAB, GR, SGP and EK are consultants for SH and were not involved in the microbial synbiotic or clinical trial design. BPC receives potential royalties from the Rome Foundation for usage of the modified Bristol Stool Form Scale for Children, which is not used in this study. AF is additionally a cofounder and stockholder of Alba Therapeutics, a company developing treatments complementary to the gluten-free diet by exploiting gut permeability. EAM is additionally on the Scientific Advisory Board of Axial Biotherapeutics, Pendulum Therapeutics, Bloom Science, Mahana Therapeutics, APC Ireland, Danone, and Amare. JFP is the Founder and Chief Scientific Officer of Diversigen, Inc. and is on the Scientific Advisory Board for 4D Pharma, PLC. CEM is co-founder of Biotia and Onegevity Health.
Clinical Trial
NCT04534036
Funding Statement
This study was funded by Seed Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of IntegReview IRB gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All software used in this project is available at https://github.com/b-tierney/pds08. Due to the clinical nature of this study, data is available upon request.
